Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Berlin

Showing results (171-180 of 248) with videos related to

Pageof 25
Sort By:
Investigational New Drugs|March 30, 2017
Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRASEmily Chan, Laura W Goff, Dana B Cardin, et al.
The Journal of Cell Biology|September 1, 1985
Glycosaminoglycan synthesis is depressed during mitosis and elevated during early G1S F Preston, C S Regula, P R Sager, et al.
Research Communications in Molecular Pathology and Pharmacology|August 1, 1994
Effects of novel antiarrhythmic agents, BRB-I-28 and its derivatives, on the heart mitochondrial respiratory chain and sarcoplasmic reticulum Ca(2+)-ATPaseC L Chen, S Sangiah, C A Yu, et al.
Arzneimittel-Forschung|June 1, 1995
Pharmacokinetics and plasma protein binding of the new potent class III antiarrhythmic agent 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3, 7-diazabicyclo[3.3.1]nonane dihydroperchlorateC L Chen, S Sangiah, J D Roder, et al.
The Oncologist|December 13, 2025
Choice of oncologist and influencing factors: analysis of the Pancreatic Cancer Action Network registryRajiv Agarwal, Jennifer G Whisenant, Lili Sun, et al.
Cancer|July 19, 2006
Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancerHoward S Hochster, Daniel G Haller, Aimery de Gramont, et al.
Oncology|June 26, 2004
Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology groupRobert C Shepard, Donna E Levy, Jordan D Berlin, et al.
American Journal of Clinical Oncology|March 17, 2017
A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic CancerDana B Cardin, Ramya Thota, Laura W Goff, et al.
Acta Physiologica Hungarica|January 1, 1993
The comparative antiarrhythmic and proarrhythmic activity of a 3,7-diheterobicyclo[3.3.1]nonane, BRB-I-28, and lidocaine in the 1-4-day-old infarcted dog heartT Fazekas, B J Scherlag, P Mabo, et al.
European Journal of Cancer (Oxford, England : 1990)|January 9, 2013
Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancerJeffrey R Infante, Johanna C Bendell, Laura Williams Goff, et al.
Pageof 25

Showing results (171-180 of 248) with videos related to

Sort By:
Pageof 25
Investigational New Drugs|March 30, 2017
Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRASEmily Chan, Laura W Goff, Dana B Cardin, et al.
The Journal of Cell Biology|September 1, 1985
Glycosaminoglycan synthesis is depressed during mitosis and elevated during early G1S F Preston, C S Regula, P R Sager, et al.
Research Communications in Molecular Pathology and Pharmacology|August 1, 1994
Effects of novel antiarrhythmic agents, BRB-I-28 and its derivatives, on the heart mitochondrial respiratory chain and sarcoplasmic reticulum Ca(2+)-ATPaseC L Chen, S Sangiah, C A Yu, et al.
Arzneimittel-Forschung|June 1, 1995
Pharmacokinetics and plasma protein binding of the new potent class III antiarrhythmic agent 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3, 7-diazabicyclo[3.3.1]nonane dihydroperchlorateC L Chen, S Sangiah, J D Roder, et al.
The Oncologist|December 13, 2025
Choice of oncologist and influencing factors: analysis of the Pancreatic Cancer Action Network registryRajiv Agarwal, Jennifer G Whisenant, Lili Sun, et al.
Cancer|July 19, 2006
Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancerHoward S Hochster, Daniel G Haller, Aimery de Gramont, et al.
Oncology|June 26, 2004
Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology groupRobert C Shepard, Donna E Levy, Jordan D Berlin, et al.
American Journal of Clinical Oncology|March 17, 2017
A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic CancerDana B Cardin, Ramya Thota, Laura W Goff, et al.
Acta Physiologica Hungarica|January 1, 1993
The comparative antiarrhythmic and proarrhythmic activity of a 3,7-diheterobicyclo[3.3.1]nonane, BRB-I-28, and lidocaine in the 1-4-day-old infarcted dog heartT Fazekas, B J Scherlag, P Mabo, et al.
European Journal of Cancer (Oxford, England : 1990)|January 9, 2013
Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancerJeffrey R Infante, Johanna C Bendell, Laura Williams Goff, et al.
Pageof 25